BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 36372670)

  • 1. Homologous and heterologous booster vaccinations of S-268019-b, a recombinant S protein-based vaccine with a squalene-based adjuvant, enhance neutralization breadth against SARS-CoV-2 Omicron subvariants in cynomolgus macaques.
    Hashimoto M; Aoe S; Kawazu Y; Seki NM; Hashimoto K; Yoshihara K; Homma T; Sonoyama T; Omoto S
    Vaccine; 2022 Dec; 40(52):7520-7525. PubMed ID: 36372670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A spike-trimer protein-based tetravalent COVID-19 vaccine elicits enhanced breadth of neutralization against SARS-CoV-2 Omicron subvariants and other variants.
    Wang R; Huang H; Yu C; Sun C; Ma J; Kong D; Lin Y; Zhao D; Zhou S; Lu J; Cao S; Zhang Y; Luo C; Li X; Wang Y; Xie L
    Sci China Life Sci; 2023 Aug; 66(8):1818-1830. PubMed ID: 36598621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant.
    Lyke KE; Atmar RL; Islas CD; Posavad CM; Szydlo D; Paul Chourdhury R; Deming ME; Eaton A; Jackson LA; Branche AR; El Sahly HM; Rostad CA; Martin JM; Johnston C; Rupp RE; Mulligan MJ; Brady RC; Frenck RW; Bäcker M; Kottkamp AC; Babu TM; Rajakumar K; Edupuganti S; Dobrzynski D; Coler RN; Archer JI; Crandon S; Zemanek JA; Brown ER; Neuzil KM; Stephens DS; Post DJ; Nayak SU; Suthar MS; Roberts PC; Beigel JH; Montefiori DC;
    Cell Rep Med; 2022 Jul; 3(7):100679. PubMed ID: 35798000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination.
    Bellusci L; Grubbs G; Zahra FT; Forgacs D; Golding H; Ross TM; Khurana S
    Nat Commun; 2022 Aug; 13(1):4617. PubMed ID: 35941152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of a booster dose of BNT162b2 on spike-binding antibodies to SARS-CoV-2 Omicron BA.2, BA.3, BA.4 and BA.5 subvariants in infection-naïve and previously-infected individuals.
    Kuzel TG; Fu J; Anderson M; Stec M; Boler M; Behun D; Gosha A; Cloherty G; Landay A; Moy J
    Vaccine; 2023 Jan; 41(4):879-882. PubMed ID: 36572601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intranasal booster using an Omicron vaccine confers broad mucosal and systemic immunity against SARS-CoV-2 variants.
    Wang Q; Yang C; Yin L; Sun J; Wang W; Li H; Zhang Z; Chen S; Liu B; Liu Z; Shi L; Liu X; Guan S; Wang C; Qu L; Feng Y; Niu X; Feng L; Zhao J; Li P; Chen L; Zhong N
    Signal Transduct Target Ther; 2023 Apr; 8(1):167. PubMed ID: 37069171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term variations and potency of neutralizing antibodies against Omicron subvariants after CoronaVac-inactivated booster: A 7-month follow-up study.
    Li X; Yin Y; Cui Q; Huang W; Zou Q; Shen T
    J Med Virol; 2023 Jan; 95(1):e28279. PubMed ID: 36329634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal data on humoral response and neutralizing antibodies against SARS-CoV-2 Omicron BA.1 and subvariants BA.4/5 and BQ.1.1 after COVID-19 vaccination in cancer patients.
    Overheu O; Lendowski S; Quast DR; Kühn D; Vidal Blanco E; Kraeft AL; Steinmann E; Kourti E; Lugnier C; Steinmann J; Reinacher-Schick A; Pfaender S
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):10633-10644. PubMed ID: 37300723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Advax-CpG55.2™ adjuvanted recombinant spike protein vaccine protects cynomolgus macaques from a homologous SARS-CoV-2 virus challenge.
    Honda-Okubo Y; Li L; André G; Leong KH; Howerth EW; Bebin-Blackwell AG; Ross TM; Petrovsky N
    Vaccine; 2023 Jul; 41(32):4710-4718. PubMed ID: 37355452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low Neutralizing Activities to the Omicron Subvariants BN.1 and XBB.1.5 of Sera From the Individuals Vaccinated With a BA.4/5-Containing Bivalent mRNA Vaccine.
    Nham E; Kim J; Lee J; Park H; Kim J; Lee S; Choi J; Kim KT; Yoon JG; Hwang SY; Song JY; Cheong HJ; Kim WJ; Park MS; Noh JY
    Immune Netw; 2023 Dec; 23(6):e43. PubMed ID: 38188597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beta variant COVID-19 protein booster vaccine elicits durable cross-neutralization against SARS-CoV-2 variants in non-human primates.
    Pavot V; Berry C; Kishko M; Anosova NG; Li L; Tibbitts T; Huang D; Raillard A; Gautheron S; Gutzeit C; Koutsoukos M; Chicz RM; Lecouturier V
    Nat Commun; 2023 Mar; 14(1):1309. PubMed ID: 36894558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Boosting with variant-matched adenovirus-based vaccines promotes neutralizing antibody responses against SARS-CoV-2 Omicron sublineages in mice.
    Shin KS; Kim BS; Chang S; Jung IK; Park H; Park S; Shin J; Kim JH; Han SJ; Park B; Kim JO; Lee JA; Lee TY; Kang CY
    Int J Antimicrob Agents; 2024 Mar; 63(3):107082. PubMed ID: 38163552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exposure to BA.4/5 S protein drives neutralization of Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 in vaccine-experienced humans and mice.
    Muik A; Lui BG; Bacher M; Wallisch AK; Toker A; Couto CIC; Güler A; Mampilli V; Schmitt GJ; Mottl J; Ziegenhals T; Fesser S; Reinholz J; Wernig F; Schraut KG; Hefesha H; Cai H; Yang Q; Walzer KC; Grosser J; Strauss S; Finlayson A; Krüger K; Ozhelvaci O; Grikscheit K; Kohmer N; Ciesek S; Swanson KA; Vogel AB; Türeci Ö; Sahin U
    Sci Immunol; 2022 Dec; 7(78):eade9888. PubMed ID: 36378074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination.
    Assawakosri S; Kanokudom S; Chansaenroj J; Suntronwong N; Auphimai C; Nilyanimit P; Vichaiwattana P; Thongmee T; Duangchinda T; Chantima W; Pakchotanon P; Srimuan D; Thatsanatorn T; Klinfueng S; Sudhinaraset N; Mongkolsapaya J; Wanlapakorn N; Honsawek S; Poovorawan Y
    Int J Infect Dis; 2022 Sep; 122():793-801. PubMed ID: 35863731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross neutralization of SARS-CoV-2 omicron subvariants after repeated doses of COVID-19 mRNA vaccines.
    Luczkowiak J; Rivas G; Labiod N; Lasala F; Rolo M; Lora-Tamayo J; Mancheno-Losa M; Rial-Crestelo D; Pérez-Rivilla A; Folgueira MD; Delgado R
    J Med Virol; 2023 Jan; 95(1):e28268. PubMed ID: 36319593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralizing antibody response to SARS-CoV-2 bivalent mRNA vaccine in SIV-infected rhesus macaques: Enhanced immunity to XBB subvariants by two-dose vaccination.
    Faraone JN; Wang X; Qu P; Zheng YM; Vincent E; Xu H; Liu SL
    J Med Virol; 2024 Mar; 96(3):e29520. PubMed ID: 38528837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of boosted mRNA and adenoviral-vectored vaccines on immune responses to omicron BA.1 and BA.2 following the heterologous CoronaVac/AZD1222 vaccination.
    Suntronwong N; Kanokudom S; Auphimai C; Assawakosri S; Thongmee T; Vichaiwattana P; Duangchinda T; Chantima W; Pakchotanon P; Chansaenroj J; Puenpa J; Nilyanimit P; Srimuan D; Thatsanatorn T; Sudhinaraset N; Wanlapakorn N; Mongkolsapaya J; Poovorawan Y
    J Med Virol; 2022 Dec; 94(12):5713-5722. PubMed ID: 35924475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the replication and neutralization of different SARS-CoV-2 Omicron subvariants in vitro.
    Zhang Y; Lv Q; Qi F; Li F; Deng R; Liang X; Liu M; Yan Y; Bao L
    Animal Model Exp Med; 2023 Feb; 6(1):51-56. PubMed ID: 36808904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Booster with Ad26.COV2.S or Omicron-adapted vaccine enhanced immunity and efficacy against SARS-CoV-2 Omicron in macaques.
    Solforosi L; Costes LMM; Tolboom JTBM; McMahan K; Anioke T; Hope D; Murdza T; Sciacca M; Bouffard E; Barrett J; Wu C; Hachmann N; Miller J; Yu J; He X; Jacob-Dolan C; Huber SKR; Dekking L; Chamanza R; Choi Y; Boer KF; Barouch DH; Schuitemaker H; Zahn RC; Wegmann F
    Nat Commun; 2023 Apr; 14(1):1944. PubMed ID: 37029141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterologous vaccination with subunit protein vaccine induces a superior neutralizing capacity against BA.4/5-included SARS-CoV-2 variants than homologous vaccination of mRNA vaccine.
    Peng D; Zhao T; Hong W; Fu M; He C; Chen L; Ren W; Lei H; Yang J; Alu A; Ni Y; Liu J; Li J; Wang W; Shen G; Zhao Z; Yang L; Yang J; Wang Z; Tanaka Y; Lu G; Song X; Wei X
    MedComm (2020); 2023 Apr; 4(2):e238. PubMed ID: 36911160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.